Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ: ARVN )

9.160 +0.090 (+0.99%)
Streaming Delayed Price Updated: 10:31 AM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 149,982
Open 9.210
Bid (Size) 9.150 (1)
Ask (Size) 9.170 (2)
Prev. Close 9.070
Today's Range 9.050 - 9.250
52wk Range 5.935 - 37.38
Shares Outstanding 68,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapies 
From Arvinas Inc.
Via GlobeNewswire

Performance

YTD
-51.51%
-51.51%
1 Month
+6.39%
+6.39%
3 Month
-49.73%
-49.73%
6 Month
-65.46%
-65.46%
1 Year
-73.06%
-73.06%

More News

Read More
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Via Benzinga
These Analysts Revise Their Forecasts On Arvinas After Q4 Results
Via Benzinga
What 4 Analyst Ratings Have To Say About Arvinas
Via Benzinga
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
From Arvinas Inc.
Via GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month
Via Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Tuesday's session: top gainers and losers
Via Chartmill
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Via Benzinga
Gapping stocks in Tuesday's session
Via Chartmill
Crude Oil Gains 1%; Ciena Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Via Investor's Business Daily
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
Via Benzinga
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
Via Benzinga
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
Via Benzinga
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Arvinas Inc.
Via GlobeNewswire
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.